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Abstract
Background: Human African trypanosomiasis (HAT) caused by Trypanosoma brucei gambiense remains highly prevalent in
west and central Africa and is lethal if left untreated. The major problem is that the disease often evolves toward chronic or
asymptomatic forms with low and fluctuating parasitaemia producing apparently aparasitaemic serological suspects who
remain untreated because of the toxicity of the chemotherapy. Whether the different types of infections are due to host or
parasite factors has been difficult to address, since T. b. gambiense isolated from patients is often not infectious in rodents
thus limiting the variety of isolates.
Methodology/Principal findings: T. b. gambiense parasites were outgrown directly from the cerebrospinal fluid of infected
patients by in vitro culture and analyzed for their molecular polymorphisms. Experimental murine infections showed that
these isolates could be clustered into three groups with different characteristics regarding their in vivo infection properties,
immune response and capacity for brain invasion. The first isolate induced a classical chronic infection with a fluctuating
blood parasitaemia, an invasion of the central nervous system (CNS), a trypanosome specific-antibody response and death
of the animals within 6–8 months. The second group induced a sub-chronic infection resulting in a single wave of
parasitaemia after infection, followed by a low parasitaemia with no parasites detected by microscope observations of
blood but detected by PCR, and the presence of a specific antibody response. The third isolate induced a silent infection
characterised by the absence of microscopically detectable parasites throughout, but infection was detectable by PCR
during the whole course of infection. Additionally, specific antibodies were barely detectable when mice were infected with
a low number of this group of parasites. In both sub-chronic and chronic infections, most of the mice survived more than
one year without major clinical symptoms despite an early dissemination and growth of the parasites in different organs
including the CNS, as demonstrated by bioluminescent imaging.
Conclusions/Significance: Whereas trypanosome characterisation assigned all these isolates to the homogeneous Group I
of T. b. gambiense, they clearly induce very different infections in mice thus mimicking the broad clinical diversity observed
in HAT due to T. b. gambiense. Therefore, these murine models will be very useful for the understanding of different aspects
of the physiopathology of HAT and for the development of new diagnostic tools and drugs.
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Introduction
Human African Trypanosomiasis (HAT), also called sleeping
sickness, is a widespread fatal disease in many rural areas of sub-
Saharan Africa caused by protozoan parasites of the genus
Trypanosoma transmitted by tsetse flies. Trypanosoma brucei rhodesiense
is responsible for the acute form in East Africa and Trypanosoma
brucei gambiense induces a chronic form in West and Central Africa
[1–3]. Without treatment, death occurs from either massive
parasitaemia or severe neuropathogenesis. Accurate evaluation of
the disease stage in the early haemolymphatic stage or the late
encephalitic stage is critical as the treatment for both stages is
different. Late stage is often treated with melarsoprol, which
induces a fatal reactive encephalopathy in 5% of the cases. There
is no current consensus on the diagnostic criteria for CNS
involvement and the specific indications for second stage
treatments might differ [4–6]. Diagnosis relies on the Card
Agglutination Test for Trypanosomiasis (CATT) based on the
detection of host antibodies directed against conserved major
Variable Surface Glycoproteins (VSG) of the parasite coat [7,8]
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lymph nodes or cerebrospinal fluid (CSF). However T. b. gambiense
infections in humans are known for their low parasitaemia and
current diagnostics are prone to false negative results. PCR using
specific DNA probes [9–12] and loop-mediated isothermal
amplification (LAMP) [13,14] were introduced for the detection
of the parasites in infected humans or animals providing better
sensitivity and specificity compared to parasitological methods
[15]. However experiments performed in this study and by other
groups proved that even PCR methods may be limited in the case
of very low parasitaemia. Thus, new molecular and/or serological
methods, possibly based on invariant targets are needed in field
diagnosis. Importantly, experimental models for T. b. gambiense are
limited mainly to subacute or chronic infections since only a few T.
b. gambiense isolates could be propagated in rodents such as mice
[16,17], cyclophosphamide-immunosuppressed mice [18], severely
immunodeficient mice [19] or particular rodent species, Mastomys
natalensis [20]. Therefore, the variety of T. b. gambiense isolates that
might be characterised and studied for their in vivo behavior is
limited. In this study, we have isolated a range of different T. b.
gambiense stocks from HAT patients and adapted them to in vitro
culture conditions. These isolates were characterised by molecular
fingerprinting and tested for mice infectivity. As they induced
different types of infections in BALB/c mice, ranging from chronic
to silent infections, the presence and the localization of the
parasites, as well as the immune responses of infected mice were
addressed.
Materials and Methods
Isolation and in vitro culture of parasites
CSF samples were obtained from passively or actively HAT
detected patients admitted at the Projet de Recherches Cliniques
sur la Trypanosomiase (PRCT), Daloa Ivory Coast in 1991. As a
reference center from the Ministry of Health, this institution deals
with clinical management and research of HAT. Written informed
consent was obtained from all patients in this study. The Comite
de Protection des Personnes Sud-Ouest et Outre Mer III
(cpp.soom3@u-bordeaux2.fr) decided that these procedures did
not need approval. Trypanosomes were isolated from CSF and
cultured either by in vitro culture or by intraperitoneal (i.p.)
inoculation in BALB/c mice as described in results. Occasionally,
parasites were separated from mice blood cells by anion-exchange
chromatography on DEAE-cellulose (DE-52, Whatman Biochem-
ical) [21].
Mice infection and parasitemia estimation
BALB/c J mice were purchased from Elevage Janvier (5394 Le
Genest-St-Isle-France), NOG (NOD.Cg-Prkdescid Il2rgtm1 Wjl/
Szj) and NOD/SCID mice (NOD.CB17/ICRT-Prkdescid/J)
were bred locally in specific pathogen-free conditions and used
for experiments at five to six weeks of age. All animal studies
adhered to protocols approved by the University of Bordeaux 2
animal care and use committee and the Commission de Genie
Genetique (Direction Generale de la Recherche et de l’Innova-
tion). Groups of 4–6 mice were infected i.p. with either a high load
(1–5610
6) or a low load (10
3)o fin vitro or in vivo (NOD/SCID
mice) expanded parasites in a 250 ml final volume of PBS
(phosphate-buffered saline : 137 mM NaCl, 10 mM Phosphate,
2.7 mM KCl, pH 7.4) containing 1% glucose. Trypanosomes
were also inoculated in BALB/c mice immunosuppressed 24 h
before infection with cyclophosphamide (200 mg/kg of body-
weight; Sigma-Aldrich, Saint-Quentin Fallavier, France). Mice
tail-blood was collected onto a slide and parasitaemia was
determined microscopically based on the observation of at least
200 fields at a 400 magnification. The limit of detection was
estimated at 10
4 parasites/ml. To convert the actual concentration
of parasites in the blood, a conversion table was made by diluting
known numbers of parasites in mouse blood. When parasitaemia
was higher than 10
6 parasites/ml, parasites were directly counted
in a haemacytometer by diluting the tail-blood in PBS.
Parasite DNA and total mRNA purification
Genomic DNA was isolated from the trypanosomes by standard
methods [22] and stored at 4uC until needed. Total RNA was
extracted from the trypanosomes using RNeasyH mRNA Mini Kit
(Qiagen, Hilden, Germany). mRNA was purified from total RNA
using OligotexH mRNA Minikit (Qiagen). The extracted mRNA
was kept frozen at 280uC until needed. For PCR detection, a
200 ml sample of whole blood was collected in heparinized
capillaries and DNA was extracted with the QIAamp DNA mini
kit (Qiagen) according to the manufacturer’s instructions and
stored at 220uC.
VSG analysis
To amplify only VSG-encoding transcripts, RT-PCR amplifica-
tion was performed using a forward primer designed to a conserved
nucleotide sequence of the mini-exon found at the 59 end of
trypanosome mRNAs and a reverse primer designed to a conserved
nucleotide sequence found at the 39 untranslated region of VSG
mRNAs of trypanosomes belonging to the Trypanozoon subgenus.
The forward primer used was IL07725 designed to contain a KpnI
site (59-CGG GTA CCT AGA ACA GTT TCT GTA CTA TAT
TG-39) and the reverse primer was IL07722 designed to contain a
BamHI site (59-CGG GAT CCA GGT GTT AAA ATA TA-39)
[23]. The reaction was carried out using Invitrogen One-Step RT-
PCR kit according to the protocol provided by the supplier. Briefly,
a5 0ml reaction mixture was prepared containing 0.1 mg mRNA,
0.2 mM of each primer, and 25 ml Reaction Mix 26 containing
dNTP, RT-PCR Enzyme and Buffer. RT-PCR amplification was
performed as follow: 45uC for 30 min, 94uC for 2 min, 5 touch-
down cycles (94 uC for 15 sec, from 55uCt o5 0 uC for 30 sec, 70uC
for 2 min) and 34 cycles (94uC for 15 sec, 50uC for 30 sec and 70uC
for 2 min) and finally 70uC for 10 min. RT-PCR products were
Author Summary
Trypanosoma brucei gambiense is responsible for more
than 90% of reported cases of human African trypanoso-
mosis (HAT). Infection can last for months or even years
without major signs or symptoms of infection, but if left
untreated, sleeping sickness is always fatal. In the present
study, different T. b. gambiense field isolates from the
cerebrospinal fluid of patients with HAT were adapted to
growth in vitro. These isolates belong to the homogeneous
Group 1 of T. b. gambiense, which is known to induce a
chronic infection in humans. In spite of this, these isolates
induced infections ranging from chronic to silent in mice,
with variations in parasitaemia, mouse lifespan, their ability
to invade the CNS and to elicit specific immune responses.
In addition, during infection, an unexpected early tropism
for the brain as well as the spleen and lungs was observed
using bioluminescence analysis. The murine models
presented in this work provide new insights into our
understanding of HAT and allow further studies of parasite
tropism during infection, which will be very useful for the
treatment and the diagnosis of the disease.
Murine Models for Sleeping Sickness
www.plosntds.org 2 September 2009 | Volume 3 | Issue 9 | e509purified on SephacrylH S-300 column (GE Healthcare Life Sciences,
Orsay, France) and cloned into the pTopo vector (Invitrogen, Cergy
Pontoise, France). The plasmids were used to transform Escherichia
coli XL1 blue, which were subsequently plated on selective media for
the isolationofrecombinants.Plasmidswerepurifiedfromindividual
bacterial colonies using the WizardH Plus SV Minipreps DNA
Purification System (Promega, Charbonnie `res, France). The size of
inserts was determined by PCR using vector primers and at least 10
clones of each isolate were sequenced. Similarity searches of
GenBank/NCBI database were performed with the program
BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) using the default
matrix. Alignment of two sequences was performed using the
program FASTA (http://fasta.bioch.virginia.edu/fasta_www/cgi/
search_frm2.cgi).
Microsatellites and minisatellites analysis
Microsatellite analysis of the MORF2-CA, M6C8-CA,
MT3033-AC/TC and MEST19-AT/GT loci was performed as
previously described [24] except that the PCR products were
analysed on both an ABI 377 DNA and an ABI 3130 XL
sequencer (PE, Applied Biosystems). PCR and analysis of the
PARP minisatellite locus (PE procyclin repetition) [25] was
performed as described for the microsatellites using PARP-S
(GACGATACCAATGGCACTG) and PARP-AS-6-FAM (TG-
CGAACGGAAGTGCAAC) primers.
PCR detection of parasites
In order to avoid loss of sensitivity due to blood contamination
with polymerase enzyme inhibitors [26], commercial columns for
blood DNA extraction ensuring reproducibility and a high degree
of purification were used for all samples (QIAamp DNA mini kit
from QIAGEN) [27]. As PCR detection based on a single target is
often doubtful for very low parasitaemia, three different targets
were used to validate the presence of trypanosome DNA in the
blood of infected mice: 1) KIN primer set (Kin1: 59-
GCGTTCAAAGATTGGGCAAT-39; Kin2: 59-CGCCCGA-
AAGTTCACC-39) designed by McLaughlin et al. [28] amplifying
a 360 bp product from a highly conserved and highly represented
region (100–200 copies per parasite) named ITS1 and located
between 18S and 5.8S rRNA genes, 2) TBR primer set (TBR1: 59-
CGAATATTAAACAATGCGCAG-39; TBR2: 59-AGAAC-
CATTTATTAGCTTTGTTGC-39) [29] shown to be highly
sensitive for HAT diagnosis [26,30] and targeting a 177 bp
repeated satellite DNA; and 3) the primers designed by
Deborggraeve et al., [27] and frequently used in diagnosis test
for HAT as they amplify a 106 bp sequence in conserved 18S
rRNA (18S-F: 59-CGCCAAGCTAATACATGAACCAA-39;
18S-R: 59-TAATTTCATTCATTCGCTGGACG-39). All PCR
were carried out in a final volume of 25 ml containing 0.8 mMo f
each primer, 0.2 mM of each deoxyribonucleotide, 16incubation
buffer with 2.5 mM MgCl2, 1 unit of HotStar Taq polymerase
(QIAGEN, Hilden, Germany) and 5 ml of extracted DNA. PCR
conditions with Kin, TBR and 18S primers were performed
according to the method previously described [27,31,32],
respectively. Kin1-2 primers anneal in the conserved regions of
the 18S and 5.8S rRNA genes to amplify the ITS1. TBR1-2
primers are specific for Trypanosoma brucei sensu lato [33]. 18S
primers amplify a sequence of the Trypanosomatidae 18S rRNA
gene. Briefly, PCR conditions with Kin primers were as follow: an
initial step of 15 min at 94uC to activate the HotStar Taq
polymerase; four cycles of amplification with 1 min denaturation
at 94uC, 1 min hybridization at 58uC and 1 min elongation steps
at 72uC; eight cycles of amplification with 1 min denaturation at
94uC, 1 min hybridization at 56uC and 1 min elongation steps at
72uC; 23 cycles of amplification with 1 min denaturation at 94uC,
1 min hybridization at 54uC and 1 min elongation steps at 72uC;
and a final extension step of 5 min at 72uC [31]. The amplification
conditions with TBR were an initial denaturation at 94uC for
15 min, 45 cycles of 94uC for 1 min, 56uC for 1 min and 72uC for
1 min and final extension was at 72uC for 5 min [32]. PCR
conditions with 18S primers were an initial denaturation step of
94uC for 15 min, 40 cycles of 94uC for 30 s, 60uC for 30 s, and
72uC for 30 s with a final extension at 72uC for 5 min [27]. PCR
amplification was performed in triplicate in three different assays.
Purified T. b .gambiense DNA was used as positive control and a
negative control without DNA was performed. 10 ml of reaction
samples or controls were tested on 1.5% agarose gel, stained with
0.5 mg/ml ethidium bromide. Results were positive when specific
size products were observed.
IgM quantification
Sandwich ELISA was used to quantify and to determine the
total IgM level in mice. Goat anti-mouse m-chain antibodies as a
capture antibody (Jackson ImmunoResearch, Baltimore) were
coated in a ninety-six-well microplate (Nalge Nunc International)
with 0.2 mg/well at 4uC overnight. After washing in PBS
containing 0.05% tween-20 (washing buffer) three times, the plate
was incubated with 100 ml/well of 3% BSA-PBS for 30 min at
37uC. The wells were then reacted with test samples which were
diluted in 1% BSA-PBS (100 ml/well) for 2 hours at 37uC followed
by reaction with 100 ml/well of goat anti-mouse IgM antibodies
conjugated with horseradish peroxidase (Southern Biotech Bir-
mingham, USA) diluted 1:8000 in PBS-Tween buffer for
1.5 hours at 37uC. The plate was washed in washing buffer three
times after each reaction. The development was performed by
using ABTS, 2,29-azino-di-(3-ethylbenzthiazoline sulfonic acid)
(Sigma-Aldrich Corp, Saint-Quentin Fallavier, France) and was
stopped by addition of 10 mM NaOH, 1 mM EDTA (100 ml/
well). The absorbance at 405 nm was measured. The level of
mouse IgM was normalized by mouse reference serum (Gentaur
Belgium).
Cloning, expression and purification of recombinant
proteins
The full length sequence for TgsGP was cloned into the pET-
28c(+) vector (Novagen) using specific primers (F: 59-GCTATTC-
CATGGGGATGTGGCAATTACTAGCAATAG-39 containing
NcoI site and R: 59-CCGGAATTCTTAATGGTGATGGTGA-
TGGTTGCTGTGGTGTTTGCCACTTC-39 containing EcoRI
site), expressed in E. coli BL21 bacteria according to the
manufacturer’s instructions and purified in the presence of 8 M
urea by immobilized metal ion Ni-affinity chromatography (His-
Trap, GE Healthcare). The full-length calflagin gene (Tbg17-
19576 corresponding to the 26 kDa protein isoform) was amplified
using primers containing KpnI and HindIII sites (F: 59-TCTA-
GAGGTACCAATGGGTTGCTCAGGATCCAAGAAC-39 and
R: 59-CTGCAGAAGCTTC TAGGCAGAACCCTCGGCCG-
CAGG-39) and the insert was cloned into the pMalE vector (New
England Biolabs). After expression in E. coli BL21 bacteria, the
soluble fusion protein was purified by maltose-affinity chromatog-
raphy according to the manufacturer’s instructions. The extracel-
lular domains of ISG64, ISG65 and ISG75 were amplified from
genomic DNA and cloned into pET21d. The ISG proteins were
expressed in E. coli BL21 (DE3) trxB bacteria as inclusion bodies.
After purification of the inclusion bodies the proteins were
solubilized in 6 M guanidinium hydrochloride and purified by
Ni-affinity chromatography, refolded by overnight dialysis in
20 mM Tris buffer (pH 8.0) and concentrated by Q-sepharose
Murine Models for Sleeping Sickness
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D. Robinson. The soluble recombinant antigens ISGs and
calflagin were used to coat ELISA plates (0.1 mg/well). The
antibody response to these antigens was measured in ELISA as
previously described [34] by using a 1:100 dilution of the infected
mice sera.
SDS-PAGE, immunoblotting and recombinant protein
strip test
Total protein preparations of bloodstream form trypanosomes
were obtained by lysis of live parasites with 2% (wt/v) SDS and
heating at 100uC in the presence of a protease inhibitor cocktail
(complete Mini, EDTA-free; Roche Diagnostics, GmbH). T. b.
brucei trypanosome fractions were obtained as described previously
[35]. Briefly, trypanosomes (about 10
10 cells) were washed in
phosphate saline glucose (pH 8.0) at 4uC, centrifuged and
hypotonically lysed in 15 ml of 5 mM sodium phosphate,
pH 8.0 in the presence of a protease inhibitor cocktail. After
centrifugation (44,000 g for 8 minutes), the soluble proteins and
the cytoskeleton/membrane proteins contained in the pellet
(washed four times in lysis buffer and resuspended in an equal
volume of 100 mM Tris pH 8.0) were boiled in SDS-PAGE
loading buffer. Protein preparations of 10
7 parasites (from total
lysate or each purified fraction) were loaded per well and separated
by SDS-PAGE (12%) before transfer onto polyvinyl difluoride
(PVDF) membranes (Immobilon-P; Millipore) and processed for
Western blotting as described previously [34]. Trypanosome
specific antibodies were tested by incubating the blots with infected
mice sera (diluted 1:100). For identification of potential immuno-
reactive proteins, blots were incubated with dilutions of invariant
specific antibodies: mouse anti-PFR2 monoclonal antibody
(1:500), rabbit anti-IS64, ISG65 or ISG75 polyclonal antibodies
(1:100), or a mouse anti-calflagin monoclonal antibody (culture
supernatant diluted K).
A recombinant protein strip test was developed to analyse the
mice infected immune response. Briefly, all recombinant proteins
were further purified by electroelution after SDS-PAGE and
loaded sequentially on a wide PAGE (0.5–2 mg of each protein per
strip). ISGs, TgsGP and calflagin were first separated for
15 minutes at 150 V on a 12% SDS-PAGE before loading PFR
and finishing the migration at 180 V. After blotting, nitrocellulose
membranes were cut into strips and incubated with infected mice
sera (diluted 1:100). After being washed three times in 1 M NaCl,
blots were incubated for 1 h with diluted horseradish peroxidase-
conjugated anti-rabbit or anti-mouse immunoglobulin G (IgG)
(both from Sigma) (1:10,000). Diaminobenzidine (DAB, Sigma)
was used as chromogen.
Brain immunohistochemistry
Anaesthetized mice were transcardially perfused with 50 ml of
ice cold PBS, then with 50 ml of ice cold 2% paraformaldehyde,
0.2% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4. The
brains were removed, post-fixed in fresh 2% paraformaldehyde for
5–6 hours at 4uC and cryoprotected overnight at 4uC in a 15%
sucrose 0.1 M PO4 buffer, pH 7.4. The brains were then frozen in
isopentane at 250uC on liquid nitrogen and stored at 280uC.
Sections of 12 mm were cut in cryostat and stored at 280uC [36].
The slides were thawed and dried at room temperature then fixed
again in 4% paraformaldehyde for 5 minutes. The endogenous
peroxidase activity was quenched with 3% H2O2 in PBS for
5 minutes. The slides were washed in water then in PBS. The
sections were permeabilized and saturated with blocking buffer
(1% BSA 0.3% Triton X-100 in PBS) for 30 minutes. The sections
were then incubated overnight at room temperature with
antibodies (used at a 1:10000 dilution in blocking buffer) obtained
from rabbits that were hyper immunized with a total T. b.
equiperdum protein extract. The slides were washed in PBS and
incubated with a secondary biotinylated anti-rabbit antibody
(1:200) in blocking buffer for 90 min at room temperature.
Thereafter the sections were incubated with avidin-biotin complex
reagent (Vectastain ABC peroxidase, Vector, ABCYS, Paris,
France) according to the manufacturer protocol. The immuno-
complex was visualized with a DAB kit (Vector). The sections were
dehydrated in graded alcohol, mounted with DePeX (SERVA,
Paris, France), and analyzed for the presence of trypanosomes
using a Zeiss light microscope. Control sections (without primary
antibodies) showed no specific immunostaining.
Transformation of T. b. gambiense with the Rluc-pHD309
plasmid
The Rluc-pHD309 plasmid designed for the integration of the
Renilla luciferase gene into the b-tubulin region of T. brucei Lister
427 bloodstream forms was kindly provided by F. Claes [37] . The
Amaxa NucleofectorH system (Lonza, Levallois-Perret, France)
was used. It is based upon a combination of free-set programs and
‘‘cell-type specific’’ solutions of unknown composition, which was
described for giving vastly improved transfection efficiencies for
the protozoan parasite Plasmodium. A pellet of 10
7 parasites was
resuspended in 100 ml of Basic Parasite NucleofectorH solution 2,
mixed with 15 mg of NotI linearized LucR-pHD309 plasmid and
subjected to nucleofection with program X-001. Stably transfected
trypanosomes were first cultured 24 h in supplemented IMDM
medium (Gibco) as described earlier [37] before selection by
adding increasing concentrations of hygromycin (starting and final
concentrations: 0.5 mg–3 mg/ml). Single clones, generated by
limiting dilution, were expanded and assessed by luciferase activity
quantification.
In vitro bioluminescence measuring
The Renilla Luciferase Assay System (Promega) was used to
measure in vitro luciferase activity as described by the manufac-
turer. Non-transformed Tgb1135 and Rluc-pHD309-transfected
clones were grown up to a total of 1–5610
6 parasites and
centrifuged at 1500 g for 10 min. The pellet was washed with
PBS, resuspended in 20 ml lysis buffer included in the Renilla
luciferase assay system (Promega) and subsequently added to
100 ml of the reaction mix. Renilla luciferase activity was monitored
over 5 min every 10 sec after substrate addition by using an
Optima microplate reader (BMG Labtech, Germany) and
expressed as relative light units (RLU) per mg protein.
In vivo and ex vivo real time bioluminescence imaging
At different time intervals after infection, mice were anaesthe-
tized with isofluorane and injected intravenously (retro-orbital i.v.)
or intraperitoneally (i.p.) with 20 mg of coelenterazine (Promega)
dissolved at 2 mg/ml in ethanol and subsequently 10 ml were
diluted in 90 ml of PBS. Light emission was recorded in real time
with a Biospace Imaging System (BIOSPACE lab, Paris, France).
Measurements started immediately after i.v. or i.p. substrate
injection and the results correspond to the values measured when
the signal is optimal and stable for at least 3 min. The signal was
integrated for 100 sec and values are expressed as p/s/sr
(photons/second/steradian) (maximum and minimum values are
fixed respectively at 100 and 10, smoothing=2.5). For ex vivo
bioluminescence imaging, mice were sacrificed and organs
removed and soaked for 5 min in coelenterazine (20 mg/ml
PBS) before recording signals as described before. Quantification
Murine Models for Sleeping Sickness
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For the comparison of signals from the same organ between
different mice, the signal was integrated for 100 sec, the area of the
ROI was kept constant and the intensity was given as p/s/cm
2/sr
after subtracting the background photon emission values obtained
for each organ from non infected mice.
Results
Isolation and culture adaptation of T. b. gambiense field
isolates
Isolation and growth of T. b. gambiense from patients remains
difficult and is the limiting step in analysis. Here, we have adapted
an in vitro culture system based on fibroblast feeder cells [38,39].
CSF (6–8 ml) was collected aseptically by lumbar puncture from
37 patients who were already in the second stage of HAT. After
centrifugation, half of the sample was inoculated intraperitoneally
(i.p.) into BALB/c mice for in vivo amplification. The other half
was transferred to culture medium in 24-well plates containing a
confluent feeder layer of Microtus montanus embryonic fibroblasts.
The culture medium was MEM medium [40] supplemented with
3.5% fetal calf serum and 15.5% horse serum instead of goat
serum. Kanamycin (400 mg/ml) and nystatin (400 U/ml), were
added to avoid contamination. The plates were incubated at 37uC
in a 4% CO2/96% air incubator. These conditions were optimal
for in vitro culture of low CSF parasitaemia. Following 12 days of
culture, 34/37 isolates were successfully amplified in culture
whereas only 6/37 were infective in BALB/c mice (blood isolates)
and subsequently caused chronic infections.
From these, we focused on three cultured isolates which failed to
infect immunocompetent mice: Tbg1122c, Tbg1166c and
Tbg1135c (c representing culture isolate) and one derived from a
mouse infection, Tbg945b (b representing blood isolate). The
culture isolates were rapidly adapted to axenic culture conditions,
MEM medium supplemented with 10% fetal calf serum, as
described previously [40] and cloned for further characterisation.
These clones showed a normal in vitro expansion with similar
growth rates: 15.9, 15.8 and 14.6 hour doubling time for
Tbg1122c, Tbg1166c and Tbg1135c respectively (Fig. 1A). Despite
numerous attempts, Tbg945b could not be adapted to axenic
culture conditions.
Molecular characterisation of T. b. gambiense field
isolates
T. b. gambiense comprises of two different groups: Group 1 is
characterised by its low virulence in rodents and a chronic
infection in humans, whereas Group 2 is virulent in rodents and
humans [41]. Using mini- and micro-satellite analysis [24], we
could clearly identify the 4 isolates, reported above, as Group1 T.
b. gambiense (markers genotype: MORF2,16/16; MEST19,22/22;
PE procyclin All1,15), even though polymorphism was observed
with other mini- and micro-satellite markers such as MT3033 (30/
x) and M6C8 (13/x) (Table 1). Moreover, all four isolates
expressed the Group 1 T. b. gambiense specific glycoprotein TgsGP
mRNA [10,42] (data not shown). To further characterise these
isolates, their expressed VSGs were analyzed (data not shown).
The VSG expressed by these clones are very similar (68%–96%
identity) to VSG sequences identified in the T. b. gambiense and T.
b. brucei sequence data-base (www.genedb.org).
Mice infectivity properties of T. b. gambiense field isolates
To assess infectivity of these four isolates, different experimental
models of mice were used: immunocompetent BALB/c mice,
cyclophosphamide-immunosuppressed BALB/c mice and severely
immunodeficient NOD/SCID mice. Mice were infected i.p. with
either a high load (1–5610
6) or a low load (1610
3) of parasites and
animals were monitored for parasitaemia, paresis and survival.
Immunocompetent mice inoculated with either a high or a low
load of Tbg945b parasites always developed a classical chronic
infection with successive waves of parasitaemia (undulating
between 1.2610
6 and 1.2610
7 parasites/ml) and death within
6–8 months post-infection (PI) (Fig. 1B). However, mice inoculated
with a high load of Tbg1122c or Tbg1166c parasites developed a
sub-chronic infection characterised by a single wave of parasitae-
mia (,1610
5 parasites/ml) 3–4 days PI followed by the absence of
detectable parasites in the blood by direct microscopic observation
(limit of parasitaemia detection .10
4 parasites/ml). In contrast,
mice infected with Tbg1135c parasites developed a silent infection
devoid of any detectable parasite during the 12 months of
monitoring (data not shown). Identical results were obtained when
mice were infected with a low load (10
3 parasites) of any of the
culture isolates. No parasite could be detected by microscopic
observation and most of the mice survived more than 12 months
without any clinical signs of disease.
As resistance or susceptibility to trypanosomiasis is associated
with non-specific and specific immune responses, we investigated
the infectivity of the T. b. gambiense field isolates in NOD/SCID
mice which are lymphocyte deficient and have reduced NK,
complement and macrophage activities. A low dose (1610
3
parasites) of chronic Tbg945b (not shown) or sub-chronic Tbg1122c
and Tbg1166c induced an acute infection with high parasitaemia
(.1610
9 parasites/ml) and death of animals within 10–11 or 20
days PI respectively. The silent Tbg1135c isolate induced an
infection characterised by a low parasitaemia (,10
6 parasites/ml)
lasting 50 to 60 days, followed by relapse with high parasitaemia
and death of animals (Fig. 1C). As the relapse might result from a
host adaptation, we compared the infectivity of the parasites
isolated directly from the blood after relapse (Tbg1135b) with the
infectivity of the culture isolate (Tbg1135c). Infection of NOD/
SCID mice with Tbg1135b resulted in a relapse and death of the
animals within a shorter time (30–42 days PI) compared with
Tbg1135c (50–70 days). No difference was observed for Tbg1122
and Tbg1166 culture and blood isolates (data not shown).
Furthermore, we characterised the VSG genes expressed by the
parasites before infection (Tbg1135c) and during the relapse
(Tbg1135b). Comparison of cDNA sequences encoding VSG
showed that Tbg1135b and Tbg1135c expressed different VSGs
(data not shown). These results were confirmed by the absence of
cross-reactivity between Tbg1135b and Tbg1135c by using variant
specific anti-sera (data not shown).
In order to assess the influence of the early antibody response,
the infectivity of a high load of the different blood isolates
(Tbg1122b, Tbg1166b and Tbg1135b) was tested in BALB/c mice
with or without prior administration of a high dose of
cyclophosphamide (200 mg/kg). Similar parasitaemia profiles,
characterised by an early and transient parasitaemia followed by
the absence of detectable parasites in the blood by direct
microscope observation, were observed in immunocompetent
and cyclophosphamide-treated mice (Fig. 1D). Nevertheless, the
peak of parasitaemia was higher in intensity and duration in
immunosuppressed (10
7–10
8 parasites/ml and 5 to 9 days)
compared to untreated mice (10
6 parasites/ml and 2 to 5 days).
Moreover, when BALB/c mice were treated with cyclophospha-
mide before the infection, 20% (7 out of 34 mice) of the infected
animals developed a hind leg paresis within 6–10 months PI
compared to 6% of the immunocompetent infected mice (6 out of
104 mice infected during the whole study). Parasitaemia of
cyclophosphamide-treated mice inoculated with the Tbg1135c
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more, when mice infected with Tbg1122b, Tbg1166b, Tbg1135b
and Tbg1135c were treated with cyclophosphamide during their
cryptic phase of parasitaemia, no parasite burst could be observed.
In mice infected with the chronic isolate Tbg945b, however, a
rapid relapse of the parasitaemia is always observed (data not
shown).
As low parasitaemia escapes detection by direct tail-blood
observation, we addressed the presence of parasites in blood by
specific PCR. In order to gain better specificity and sensitivity,
three different multi-copy genes present in the Trypanozoon
subgenus were targeted [27–29]. When triplicate PCR gave three
positive or three negative results for at least two of the three PCR
targets, the sample was considered as + or 2 respectively.
However, for discordant results (with only one positive PCR), the
sample was considered as doubtful (6). Parasite PCR detection
was positive until 12 months PI in all immunocompetent infected
mice irrespective of the field isolate, the parasite load and the
amplification of the parasites before inoculation (culture or blood
isolates). Nevertheless, the presence of parasites in the blood might
fluctuate during infection as some samples were found negative
during the 12 months of monitoring. Table 2 illustrates the results
obtained with mice infected with 1610
3 parasites of the silent
Tbg1135c isolate.
Non-specific and specific humoral immune response of
BALB/c mice infected with T. b. gambiense field isolates
As chronic experimental T. b. gambiense infections are charac-
terized by macroglobulinemia [43,44], we investigated the serum
immunoglobulin M (IgM) level in different infection models: mice
infected with either 1610
3 or 1610
6 trypanosomes of the chronic
(Tbg945b), sub-chronic (Tbg1122b, Tbg1135b) or silent (Tbg1135c)
isolates. Whereas Tbg945b induced a 5 to 7 fold increase in total
IgM level in BALB/c mice compared to non-infected mice, as
Figure 1. In vitro and in vivo growth characteristics of T. b. gambiense field isolates. A. In vitro culture of Tbg1122, Tbg1166 and Tbg1135
isolates after adaptation to axenic culture conditions. Cultures were seeded with adapted trypanosomes (5.10
4/ml) in supplemented MEM medium
and enumerated every 24 h. The mean trypanosome densities6standard error of the mean of 4 independent cultures is presented. Similar doubling
times were obtained with the three isolates (15.9 h, 15.8 h and 14.6 h respectively). B–D. Parasitaemia levels in immunocompetent (BALB/c),
immunodeficient (NOD/SCID and cyclophosphamide-treated BALB/c) mice infected with the different field isolates. Parasitaemia was measured from
tail-blood either by direct observation of the wet films under the microscope or by using a haemacytometer. The limit of detection was estimated at
about 10
4 parasites/ml. B. Represents the results of one representative BALB/c mouse (n=6) infected i.p. with 10
6 of the Tbg945 blood isolate. All
infected mice showed successive waves of parasitaemia and died within 6–8 months PI. C. Represents the mean parasitaemia in NOD/SCID mice
infected with 10
3 Tbg1122c (n=4), Tbg1166c (n=6), Tbg1135c (n=9) or Tbg1135b (n=10) isolates. D. Represents the results of one representative
BALB/c mouse infected with 1–5610
6 Tbg1122b, Tbg1166b (n=10) or Tbg1135b blood (n=6) isolates with (+cyclo) or without (2cyclo) prior
administration (24 h before infection) of cyclophosphamide (200 mg/kg). Solid symbols indicate culture isolates, open symbols indicate blood
isolates of Tbg1166 (m , n), Tbg1122 (& , %) and Tbg1135 (N , #).
doi:10.1371/journal.pntd.0000509.g001
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infections was only slightly (less than 2 fold) increased (Fig. 2).
The capacity of trypanosome infections to induce a specific
immune response was tested by Western blotting against total
parasite extracts subjected to SDS-PAGE (whole lysates of T. b.
gambiense Tbg1122 or T. b. brucei Tbb427). The sera of mice infected
with 1610
3 parasites of Tbg945b or Tbg1122b strongly recognised
a large panel of proteins with MW ranging from 20 to 100 kDa as
soon as one month PI (Fig. 3A) and during the entire time course
of infection (identical profiles were observed 9 and 12 months PI,
data not shown). The additional specific band strongly recognised
by the sera of mice infected with Tbg1122 is most likely to
correspond to the VSG expressed by Tbg1122. The response was
less intense with the sub-chronic Tbg1135b isolate (1610
3
parasites) and no reactivity was observed with the sera of mice
infected with the silent Tbg1135c isolate (1610
3 parasites) with the
exception of one serum out of four which recognised a single band
migrating at 70 kDa at 9 months PI (data not shown). Since
identical Western blot profiles were obtained with whole cell
protein extracts of Tbb427 (T), the sera were tested against two
Tbb427 trypanosome lysate fractions (Fig. 3B): a soluble protein
fraction (F1) and a cytoskeleton/membrane fraction (F2). As
shown in Figure 3B and C, most of the proteins recognised by the
sera belong to the cytoskeleton/membrane fraction.
Characterisation of trypanosome antigens recognised
during infection
In order to further identify the antigens recognized by immune
sera, we compared the Western blot profiles obtained with the sera
of infected mice with those obtained with specific antibodies
directed against already known immunogenic proteins belonging
to the cytoskeleton/membrane fraction: the invariant surface
glycoproteins, ISGs (MW 64, 65 or 75 kDa) [45–47], the
Table 1. Minisatellites and microsatellites analyses.
Identification Focus Year Host Microsatellites (Repetition number or size)
MORF2-CA M6C8-CA MT3033-AC/TC MEST19-TA/CA PE procyclin repetition number
All. 1-2 All. 1-2 All. 1-2 All. 1-2 All. 1-2-3-4-5
Trypanosoma brucei gambiense Type I
27/7 Ivory Coast Human 16 - 16 13 - 53 30 - 48 22 - 22 15 – 20 – 21 - 24
Zakaria Ivory Coast Human 16 - 16 13 - 53 30 - 49 22 - 22 15 – 20 – 21 - 24
LiTat-1/1 Ivory Coast1952 Human 16 - 16 13 - 44 30 - 43 22 - 22 15 – 19 – 20 - 21
1122 Ivory Coast1991 Human 16 - 16 13 - 44 30 - 44 22 - 22 15 – 20 - 21
1166 Ivory Coast1991 Human 16 - 16 13 - 44 30 - 43 22 - 22 15 – 20 - 21
1135 Ivory Coast1991 Human 16 - 16 13 - 43 30 - 43 22 - 22 15 – 20 - 21
945 Ivory Coast1991 Human 16 - 16 13 - 43 30 - 30 22 - 22 15 – 20 - 21
Trypanosoma brucei gambiense Type II (Bouafle ´)
HTAG/107-1 Ivory Coast1986 Human 13 - 48 23 - 37 14 - 14 24 - 25 21 – 22 – 23 – 26 - 28
TH2 (78E) Ivory Coast1978 Human 13 - 49 38 - 48 19 - 22 31 - 40 22 – 23 – 26 - 28
The genotype of each isolate (Tbg945, Tbg1122, Tbg1166 and Tbg1135) was analyzed as described earlier [24] by determining the number of repeats per allele and
compared to group 1 and 2 genotypes.
doi:10.1371/journal.pntd.0000509.t001
Table 2. PCR detection of Trypanosomes in the blood of
BALB/c mice infected with 10
3 parasites of the silent Tbg1135c
isolate.
BALB/c mice Months post-infection
249
a ++6
b +++
c 6 ++
d + 6 +
e +++
Detection is based on the amplification of 3 Trypanosoma brucei specific gene
targets. The + sign represents a positive result (2–3 out of 3 targets
amplification). 6 represents a doubtful result (1 out of 3 targets amplification).
doi:10.1371/journal.pntd.0000509.t002
Figure 2. Time course of total serum IgM levels in BALB/c mice
infected with different T. b. gambiense field isolates. Four mice
were infected with either a low (10
3) or a high (10
6) load of Tbg945b,
Tbg1122b, Tbg1135b or Tbg1135c isolates then IgM levels were
quantified by ELISA test 1 month (black bars), 3 months (white bars),
5 months (gray bars) and 12 months (hatched bars) after infection. IgM
levels are expressed as a multiple (mean6standard error) of the level
before infection.
doi:10.1371/journal.pntd.0000509.g002
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calflagin isoform (MW 26 kDa) [50] (Fig. 3D). Indeed, ISGs and
PFR-specific antibodies recognised proteins from whole cell lysates
(Fig. 3D) or the cytoskeleton/membrane fraction (data not shown)
with the same molecular weight of those recognised by the sera of
infected mice. Furthermore, a calflagin-specific monoclonal
antibody (T. Baltz; unpublished results) recognised the three
members of the calflagin family (44, 26 and 23 kDa) as did the sera
of mice infected with trypanosomes (indicated by arrows in
Fig. 3B). These results led us to test these antigens as recombinant
proteins by immunoblotting after separation by SDS-PAGE. The
recombinant T. b. gambiense specific glycoprotein, TgsGP (MW
47 kDa) [42] was included in the test (Fig. 4). All infected mice
strongly reacted as soon as one month PI independently of the
parasite load inoculated, with the exception of the silent Tbg1135c
for which a high load was necessary to elicit a significant antibody
response. No response was observed in mice infected with a low
number of Tbg1135c except in one animal (out of 4) for which only
PFR was detected. The three antigens ISG65, ISG75 and calflagin
were more consistently and strongly recognised, compared to PFR
and TgsGP. Interestingly, sera of mice infected with blood isolates
always recognised the recombinant proteins earlier and more
strongly than the sera of mice infected with culture isolates. To
further assess the antibody responses during infection, relative
antibody titers were evaluated by ELISA against the native soluble
recombinant proteins (ISGs and calflagin). Figure 5 illustrates the
results obtained with the sera of mice infected with a low number
(1610
3) of parasites except for the silent Tbg1135c isolate for
which the data obtained with a high cell number was included. As
observed by Western blotting, all isolates except Tbg1135c (even at
high load) elicited a significant antibody response against the
recombinant proteins. ISG64, ISG65 and calflagin were some of
the major immunogenic antigens detected in mice infected with
the chronic Tbg945 isolate and the sub-chronic Tbg1122b,
Tbg1122c (Fig. 5) and Tbg1166c (data not shown) isolates. Low
titers of ISG64, ISG65 and calflagin antibodies were detected in
mice infected with a low load of Tbg1135b.
Parasite tissue localisation in BALB/c mice infected with
T. b. gambiense field isolates
In order to address CNS invasion in the different models, the
presence of parasites in the brain tissues was initially investigated
by immunohistochemistry from microtome derived brain sections.
In the chronic model (BALB/c mice infected with 1610
6 Tbg945b
parasites, n=2), parasitic invasion of the brain parenchyma was
observed as soon as 4 months PI without any sign of paresis of the
mice. Numerous parasites were observed in the olfactory bulb, and
in the forebrain where they were widely spread in cerebral cortex,
hippocampus and hypothalamus but absent from the myelinated
fiber tracts (optic chiasma or corpus callosum). Fewer parasites
were present in the brain stem (Fig. 6 A1, A2 and A3). However,
no parasites could be detected in the brain of BALB/c mice
(n=2), 9 months after infection with sub-chronic Tbg1166c and
without clinical signs of disease. In contrast, when mice were
cyclophosphamide-immunosuppressed before infection with the
sub-chronic isolates, histological examination of the brain of two of
the four mice with hind feet paresis (Tbg1166c and Tbg1122c 6 and
10 months after infection respectively) clearly showed a significant
brain invasion by the parasite, restricted to the olfactory bulb and
mainly to the brain stem, where they are localised in fiber tracts
such as the spinal trigeminal tract (Fig. 6 A4 and A5). In one
animal (Tbg1122c infected), clusters of parasites could be detected
in the cerebellum near a blood vessel (Fig. 6 A6). The limited
sensitivity of histological examination due to the fact that only the
presence of labelled whole trypanosomes was considered as
positive led us to verify the absence of parasites in the brain of
mice infected with the sub-chronic isolates (Tbg1135b, Tbg1122b)
by PCR. Nine out of 10 mice tested 5 to 10 months PI, were
Figure 3. Immunoblotting analysis of the trypanosome antigens recognised during BALB/c mice infections and identification of
potential immunoreactive proteins. Different trypanosome protein extracts: (3A,D) Tbg1122b total lysate, (3B) Tbb427 total lysate (T) and
Tbb427 fractions containing the soluble proteins (F1) or cytoskeleton/membrane proteins (F2), (3C) Tbb427 cytoskeleton/membrane fraction (F2)
were subjected to SDS-PAGE and tested by Western blotting against different sera from BALB/c (n=4) mice infected with (10
3) parasites, (3A–C): sera
from Tbg945b (1), Tbg1122b (2), Tbg1135b (3), Tbg1135c (4); non-infected control mice (5) or (3D) antibodies specific for cytoskeleton or membrane
proteins: rabbit polyclonal antibodies directed against ISG64 (6), ISG65 (7), ISG75 (8), mouse monoclonal antibodies recognizing PFR2 (9) or calflagin
(10). A–C represents the results of one representative immunoblot out of 4 mice tested.
doi:10.1371/journal.pntd.0000509.g003
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all models but with differing levels of severity.
The development of an in vivo luminescent imaging for T. b. brucei
using RenillaLuciferase-tagged trypanosomes[37] allowed us to apply
this method to T. b. gambiense.T h eTbg1135c isolate was transfected
with the Renilla Luciferase (LucR) vector using the Amaxa
Nucleofector system. Stable transfectants (LucR-Tbg1135c) were
selected, clonally expanded and tested for in vitro luciferase activity
(807659 RLU/mg protein) as described in Material and Methods.
LucR-Tbg1135bparasites wereobtained by infecting NOG micewith
10
6 LucR-Tbg1135c and 15–20 days after infection R-Luc activity
was measured to assess that they constitutively express R-Luc.
In order to identify the spatio-temporal localisation of parasites in
sub-chronic and silentinfections,1610
6 trypanosomesderived from
Figure4. Reactivitypatterns ofimmunoreactive invariant trypanosome proteinsduring BALB/c mice infections. Four mice were infected
with either a low (10
3) or a high (10
6) load of Tbg945b, Tbg1122b, Tbg1166b, Tbg1135b or Tbg1135c isolates and their sera collected at different time
points were tested by Western blotting (1/100 dilution) against a strip loaded with recombinant protein: 0.5 mg PFR and ISG75, 1 mg ISG65, ISG64 and
TgsGP and 2 mg calflagin. The data are representative of one immunoblot out of 4 mice tested. NI represents the control sera before infection.
doi:10.1371/journal.pntd.0000509.g004
Figure 5. Kinetics of antibody responses to native ISGs and calflagin in BALB/c mice infected with T. b. gambiense field isolates. Sera
from mice infected with 10
3 parasites of Tbg945b (no symbol), Tbg1122c (&), Tbg1122b (%), Tbg1135c (x), Tbg1135b (#) or with 10
6 parasites of
Tbg1135c (N) were collected at different time points PI and tested by ELISA for their reactivity against native ISG64, ISG65, ISG75 and calflagin. Results
in Tbg1166b (data not shown) and Tbg1122b infections were similar. All isolates elicited an antibody response against the recombinant proteins,
except the silent Tbg1135c (even with a high load of parasites). Each point represents the mean6standard error of 5 mice.
doi:10.1371/journal.pntd.0000509.g005
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BALB/c mice treated with cyclophosphamide, (n=2 for each
isolate) or untreated (n=6 and n=2 respectively). The temporal
course of invasion and the tissue tropism of the parasite were
monitored using real-time in vivo bioluminescence imaging (BLI)
with coelenterazine as substrate. The BLI signals, either after an i.v.
ori.p.injection,ofthe substratewere analyzedintheuntreatedmice
at different weeks PI. BLI signals were detected as soon as 2 weeks
PI in the vicinity of the peritoneum (2 out of 6 mice) and in the front
region of the head (4 out of 6 mice) in mice infected with LucR-
Tbg1135b while no parasite could be detected in the blood. Both
mice infected with the silent LucR-Tbg1135c gave BLI signals 4
weeks PI. Despite the heterogeneity of the individual values when
comparingthe data,BLIsignals eitherremained steadyor increased
slightly during the time course of infection and a BLI signal was
detected in all mice 8–13 weeks PI (Fig. 6B). As described previously
[51] higher signals were recorded in the head when the substrate
was injected i.v rather than i.p. probably due to a better local
availability of the substrate. When the dorsal face of the mouse was
exposed, the signal was higher in the front region of the head. In
cyclophosphamide-treated mice, BLI signals were only recorded
long after infection (8 and 9 weeks PI for Tbg1135c and Tbg1135b
respectively) due to the fact that mice become very sensitive to
anaesthesia and often die spontaneously. The BLI signals and their
increase over time were much higher in the Tbg1135b-infected mice
than in those infected with Tbg1135c (Fig. 6B).
Figure 6. Analysis of T. b. gambiense organs and central nervous system invasion in BALB/c-infected mice. A. Immunohistochemical
detection of trypanosomes in the brains of mice (n=2, only results from one mouse are shown) infected for 4 months with 10
6 parasites of the
Tbg945b isolate (1, 2, 3) and of paralyzed mice (n=2) treated with cyclophosphamide before infection with either 5610
6 parasites of subchronic
Tbg1122c or Tbg1166c isolates. Paralysis occurred 10 and 6 months PI with Tbg1122c and Tbg1166c isolates respectively. Only results from Tbg1122c
are shown (4, 5, 6). A1 and A4 correspond to an olfactory bulb coronal section, A2 to a forebrain section, A3 and A5 to brain stem sections and A6 to
a cerebellum section. Whole brain invasion was observed with the chronic isolate at an advanced stage of the disease (4 months PI, death within 6–8
months). Invasion was restricted to the olfactory bulb and the brain stem (including the cerebellum for Tbg1122c) in paralyzed mice infected with the
sub-chronic isolates after treatment with cyclophosphamide. No invasion was observed in mice (n=2) infected for 9 months with 5610
6 parasites of
subchronic Tbg1166c isolate (data not shown). B. Spatial distribution of R-Luc activity in animals developing a sub-chronic or a silent infection and
treated with or without cyclophosphamide (+/2cyclo). BALB/c mice were either directly infected with 10
6 LucR-Tbg1135b (n=6) or LucR-Tbg1135c
(n=2) or treated 24 h before infection with cyclophosphamide (n=2). At different time PI, mice were anaesthetized and injected intravenously (i.v.,
retro-orbital) or intraperitoneally (i.p.) with coelenterazine and BLI signals were recorded in real time with a Biospace Imaging System. The panels
show dorsal and ventral images of 2 representative mice infected for 8–11 weeks: LucR-Tbg1135b (11 weeks), LucR-Tbg1135c (10 weeks), LucR-
Tbg1135b+cyclo (9 weeks), LucR-Tbg1135+cyclo (8 weeks). C. Spatial distribution of R-Luc activity in organs removed from LucR-Tbg1135 infected
BALB/c mice. The different organs shown in this figure were isolated from mice: (1) non infected (control) (2) infected for 18 weeks with 10
6 LucR-
Tbg1135b, (3) infected for 18 weeks with 10
6 LucR-Tbg1135c, (4) pre-treated with cyclophosphamide and infected for 16 weeks with 10
6 LucR-
Tbg1135c. Quantification data of light emission signals for ROI delimitating each organ are given in photons/second/cm
2/steradian (p/sec/cm
2/sr).
doi:10.1371/journal.pntd.0000509.g006
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ex vivo BLI on individual organs (brain, lung, spleen, stomach,
kidneys, heart, liver and intestines). One animal per group (16–18
weeks PI with Tbg1135b, Tbg1135c, or Tbg1135c after cyclophos-
phamide treatment) was sacrificed and the dissected organs
incubated with coelenterazine and analysed for photon emission.
In all animals marked BLI signals (.7 000 photon/s/cm
2/sr)
were observed in the brain, lung and spleen. The other organs
displayed no signal or a background signal when properly
dissected from the adipose tissue which always gave a positive
signal (data not shown). Further histology analyses are needed to
characterize the tissue. In the brain, the signal distribution either
covered the whole organ (mouse infected with Tbg1135b fig. 6C)
or was restricted mainly to the olfactory bulb and the cerebellum
region (mouse infected with Tbg1135c fig. 6C). The distribution
was independent of cyclophosphamide treatment.
Discussion
The successful aim of this study was to provide a murine model
based on T. b. gambiense isolates to further the understanding of
chronic HAT and its epidemiology. So far, most of the host-
parasite model systems have been developed with the livestock
pathogen Trypanosoma brucei brucei, which often induces high
parasitaemia that requires treatment with drugs such as suramin
or berenil (diminazene aceturate). Since these drugs do not cross
the blood-brain barrier (BBB), parasites are cleared from the
vascular compartment but not the CNS thereby inducing a
chronic infection that could reflect HAT [6,52–54]. As most of the
T. b. gambiense isolates are not infectious in mice, T. b. gambiense
models relied on a few rodent adapted isolates producing subacute
or chronic infections [16–20] characterized by short animal
survival time. The major challenge for the development of a long
lasting chronic model relied on the adaptation of T. b. gambiense
directly isolated from the CSF of HAT patients to axenic culture
conditions. The presence of fibroblasts as feeder cells and the
origin of the sera supplementing the culture medium were the
main factors for success in the isolation of 34 (out of 37) field stocks
[40]. After rapid adaptation to axenic culture, to avoid growth
selection, 3 field isolates were cloned and tested for their infectivity
in immunocompetent and immunodeficient mice. These isolates
induced infections ranging from chronic to silent in immunocom-
petent BALB/c mice. In the chronic infection (Tbg945), successive
waves of parasitaemia were observed and all infected mice died
within 8 months. The sub-chronic (Tbg1122, Tbg1166 and
Tbg1135b) and silent (Tbg1135c) isolates induced longer lasting
infections (more than 12 months) without, in most mice, any
clinical sign of disease. In addition, parasitaemia was undetectable
by microscopy, except for the sub-chronic isolates in which a single
low peak of parasitaemia was observed soon after infection.
Nevertheless, we clearly provide evidence for the persistence of
parasites in all infected mice by PCR and by in vivo biolumines-
cence imaging. Whether the different types of infections are due to
host or parasite factors has been addressed by molecular
characterisation of the isolates and by analysing the antibody
immune responses elicited during the infections. The character-
isation of the isolates by micro and mini-satellite analysis showed
that all three isolates belonged to the homogeneous group I
although some genetic polymorphism was observed despite their
common origin from the same endemic area (Daloa, Ivory Coast).
These minor genotype differences could explain the differences in
infectivity of the isolates. Infection of immunodeficient NOD/
SCID mice demonstrated that the innate immune response was
not sufficient to contain an infection with T. b. gambiense isolates,
except for the silent Tbg1135c for which the level of parasitaemia
was controlled during 1–2 months before fatal parasitaemia
involving a new trypanosome variant Tbg1135b. Furthermore,
parasite host-adaptation occurred, because Tbg1135b is more
virulent than Tbg1135c. These results demonstrate that mice
infectivity properties are not only the result of isolate specificities
but may change during adaptation to a new host. Table 3
summarizes the different biological properties of the T. b. gambiense
field isolates.
HAT resulting from T. b. gambiense infection and experimental
chronic trypanosomiasis induce a non-specific immune response
resulting in high blood IgM levels, which is one of the criteria used
for diagnosis [44,55,56]. In our mice models we clearly
demonstrate that the level of macroglobulinemia is linked with
the parasite load. Whereas total IgM level increased significantly
in the chronic Tbg945 infection compared to non-immune mice,
sub-chronic or silent isolates did not induce a significant increase
of total IgM. Therefore in HAT, absence of macroglobulinemia
cannot be considered as a parameter of absence of infection.
Additionally, specific antibody responses were induced in the
three infection models as demonstrated by Western blotting
against total trypanosome lysates, except in mice infected with a
low load of the silent isolate, Tbg1135c. We identified several
immunogenic antigens belonging to the cytoskeleton/membrane
fraction, which are recognised by the infected mice in a similar
fashion as the total lysate. By analyzing the banding pattern of the
purified recombinant protein strips, ISG65, ISG75 and calflagin
always gave a positive reaction. Analyzing the kinetics of antibody
responses by ELISA showed that ISG64, ISG65 and calflagin were
some of the major invariant antigens which stimulated antibodies
in all infections except the silent Tbg1135c, even with a high load
of parasites. Taken together, specific antibody responses could be
clearly detected along the time course of all experimental T. b.
gambiense infections except when mice were infected with a low
load of the silent Tbg1135c isolate. These markers may provide
Table 3. Biological properties of type 1 T. b. gambiense field isolates.
In vitro culture Mice infection
BALB/c NOD/SCID
Virulence survival Total IgM level Antibody response Brain Invasion Virulence survival
945 2 Chronic,8 months + +++ High Acute
1122, 1166 + Subchronic.12 months 2 ++ Low Acute
1135c + Silent.12 months 2 6 Low Acute after controlled
infection
doi:10.1371/journal.pntd.0000509.t003
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trypanosome invariant antigens. Currently, serological diagnosis of
HAT relies on the use of selected highly immunogenic VSGs
expressed early in infection by all T. b. gambiense isolates (CATT or
LATEX/T. b. gambiense tests). However, HAT with a parasitaemia
that is undetectable by microscopy, as well as the absence of
trypanosome-specific antibodies, remains a major concern in the
field. Only PCR will be sensitive enough for diagnosis if performed
at least twice during the course of infection.
Recently, innovation in imaging technology and the discovery
of new bioluminescent markers such as the Renilla luciferase
facilitated the development of bioluminescent-transfected patho-
gens thereby allowing the in vivo spatio-temporal course of
infection to be followed [57]. The development of in vivo
luminescent imaging for T. b. brucei using Renilla Luciferase-tagged
trypanosomes [37] and the transfection conditions for T. b.
gambiense, allowed us to obtain stable LucR-transfected trypano-
somes. These are LucR-1135b, which behaves as a sub-chronic
isolate and Tbg1135c, which remains cryptic during the whole
course of infection. BLI monitoring of infected BALB/c mice
revealed a rapid spread and expansion of parasites (2–4 weeks after
inoculation) at two important anatomical sites: the front of the
head and the abdomen. We showed that early after infection (16–
20 weeks), during the cryptic phase of parasitaemia, trypanosomes
are found in a privileged site such as the brain and in other organs
such as the spleen and lungs. No specific signal was detected in the
heart, liver or kidneys. The maintenance or slight increase over
time of the photon emission could only result from active parasite
proliferation involving new antigenic variants escaping the
immune response of the host but we cannot exclude that parasites
may also accumulate in small capillaries (lungs) after proliferation.
It is clear that trypanosome proliferation takes place in a limited
space where the parasites probably find the proper growth
conditions such as endothelial cell attachment [58], a reducing
environment [40], nutrients, absence of trypanolytic compounds
which might be present in the peripheral blood etc. At that stage of
the study it was not possible to precisely localise the parasites
within the spleen and lungs. In the brain, however, photon
emission was always localised in the olfactory lobes and the
cerebellum, the signal was spread over the whole organ in the case
of the mouse infected with Tbg1135b. The signal distribution
reflects both the parasites present in the vascular compartment
and those, which could have already infiltrated the brain
parenchyma. Nevertheless, the pattern obtained by BLI with the
mice infected with Tbg1135c after cyclophosphamide treatment is
similar to that obtained by immunohistochemistry revealing that
parasite brain invasion is mainly restricted to the olfactory bulb,
brain stem and cerebellum, a location which might be linked to
mouse hind-leg paralysis.
One can speculate that parasites grow attached to specific
microvascular endothelial cells [58] present in the brain, spleen or
lungs where they undergo antigenic variation and induce variant-
specific antibodies. This stimulated immune response may result in
trypanolytic activity inducing the release of parasite proteins. In
particular, cysteine proteases may be released, which have been
shown to induce the activation of brain microvascular endothelial
cells allowing the transendothelial migration of T. b. rhodesiense in
vitro [59,60]. Furthermore, the continuous lysis of trypanosomes
will generate immune complexes, which will elicit a complement-
mediated local inflammation establishing the conditions for the
parasite to progressively invade the brain through the BBB
[60,61]. Once the parasites have crossed the BBB, they are
protected from the immune response and most of the trypanocidal
drugs. It is clear from this study that T. b. gambiense spreads rapidly
(within weeks) to organs such as the brain, lungs and spleen where
they multiply and can invade the parenchyma. The severity of the
disease and brain invasion clearly depends on the isolate. A
Tbg945 induced chronic infection, with waves of parasitaemia, will
elicit a more severe inflammation in the blood vessels than the sub-
chronic or silent isolates, which will result in a more severe
invasion of the brain parenchyma as observed by immunohisto-
chemistry and additionally, the rapid death of the animals. Studies
defining parasite virulence and host determinants for the disease
have been essentially based on T. b. brucei mouse infections, in
which the course of the disease is rather acute. Furthermore, it has
been shown on a human in vitro model that T. b. rhodesiense is able to
cross the BBB more efficiently than T. b. brucei [58]. This
peculiarity defines T. b. rhodesiense as a typical CNS tropic organism
whose capacity to invade the brain parenchyma in vivo will be
highly enhanced depending on the severity of the immune
response. Our preliminary results on T. b. gambiense brain invasion
in mice indicate a major tropism for the olfactory bulb for all
isolates, which has not been observed for T. b. brucei. The early
tropism of the silent Tbg1135c isolate and the long lasting,
asymptomatic phase in mice are in favour of either, a slow
invasion of the organs and/or a slow progression within the
organs. Compared to T. b. brucei infections, murine infections of T.
b. gambiense field isolates better mimic the different progressions of
gambiense sleeping sickness. In particular, the asymptomatic
phase raises the question of ‘‘trypano-tolerance’’ not only in
humans but also in animals, which might constitute the natural
reservoir for the disease. Indeed, numerous studies suggest that
asymptomatic and/or fluctuating carriers with undetectable
parasitaemia may occur in the field associated with epidemiolog-
ical incidences [3,12,62,63]. Furthermore, even if studies have
been dedicated to identify markers for the determination of disease
stage [64,65], the duration of the stages, the parasite progression at
different stages within the organs, their accessibility to current
therapeutic treatments and the outcome of treatment [66,67] are
still elusive. These questions will be addressed [3] by combining
different experimental approaches: treatment of infected animals
with drugs such as suramin or berenil (diminazene aceturate)
which do not cross the BBB and therefore clear the parasites from
the vascular compartment and non sedated (to avoid anaesthesia
which might kill infected animals) animal BLI analysis, BLI and
immunohistochemical analysis of dissected organs, infection of
mice with T. b. gambiense isolates expressing GFP and optical
fluorescence analysis on tissue sections etc.
In conclusion, a method has been developed for a reliable
adaptation of T. b. gambiense isolated from patients to growth in
mice. Previous protocols for the adaptation of T. b. gambiense to
growth in mice were limited. The progression of three different
isolates grown in mice were characterised and each produced
different outcomes that mirror the different types of human
disease: chronic, sub-chronic and silent. The availability of mouse
models with a range of disease states will greatly benefit further
investigation of disease progression. The murine infections were
characterised by measuring parasite growth and the hosts’
antibody response. In addition, the distribution of the parasites
in the host was determined for one trypanosome isolate by
introducing a R-Luc transgene so that it could be visualised in the
host. Early in the infection, there was an unexpected tropism not
only for the brain but also for other organs such as the spleen and
lungs. Using the mouse model we have developed, we can address
important questions regarding the molecular mechanisms involved
in virulence, sequestration and tropism of T. b. gambiense in a more
focused manner. This has implications in understanding parasite
biology, chemotaxis, blood brain barrier, immune response,
Murine Models for Sleeping Sickness
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determination during disease progression, and more efficient and
less toxic trypanocidal compounds.
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